Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Merck KGaA Denied Rights To ImClone Antibody As Part Of Erbitux Partnership

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

ImClone’s agreement with Bristol for Erbitux in North America does cover the follow-on antibody IMC-11F8.

You may also be interested in...



ImClone Receives Payment From Merck KGaA For Changes To Erbitux Agreement

ImClone consented to Merck’s sublicense of certain IP rights relating to anti-EGFR antibody technology to Takeda.

ImClone Receives Payment From Merck KGaA For Changes To Erbitux Agreement

ImClone consented to Merck’s sublicense of certain IP rights relating to anti-EGFR antibody technology to Takeda.

Erbitux Pricing Could Be Modified With Longer Treatment Cycles

Cetuximab was approved March 1 for treatment of advanced head and neck cancer.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS064091

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By